Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update.

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Repulsive guidance molecule-a (RGMa) plays a complex role in the central nervous system (CNS).
• Its involvement spans various neurological conditions, including neurodegenerative and acute injuries.
• Understanding RGMa's mechanisms is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To comprehensively review the role of RGMa in CNS pathologies.
• To discuss the mechanisms underlying RGMa's contribution to neuroinflammation, degeneration, and regeneration.
• To evaluate the therapeutic potential of RGMa inhibition.

Main Methods:

• Literature review of preclinical and clinical studies on RGMa in neurological disorders.
• Analysis of RGMa's involvement in neuroinflammation, neuronal survival, and axonal regeneration.
• Examination of immunomodulatory and neurogenic effects of RGMa.

Main Results:

• RGMa overexpression is linked to negative outcomes like neuroinflammation and synaptic loss.
• Inhibition of RGMa, using agents such as elezanumab, demonstrates potential for enhancing neuronal survival and functional recovery.
• RGMa influences immunomodulation and neurogenesis, indicating therapeutic relevance.

Conclusions:

• RGMa is a critical factor in CNS pathology across a spectrum of neurological disorders.
• Targeting RGMa offers a promising therapeutic avenue for treating neurological conditions.
• Further clinical trials are necessary to confirm the safety and efficacy of RGMa-targeted therapies.